Adaptive Biotechnologies Corporation
ADPT
$9.29
-$0.22-2.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 189.53M | 178.96M | 177.28M | 168.77M | 174.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 189.53M | 178.96M | 177.28M | 168.77M | 174.50M |
| Cost of Revenue | 36.66M | 37.73M | 29.08M | 36.13M | 36.08M |
| Gross Profit | 152.87M | 141.22M | 148.20M | 132.64M | 138.42M |
| SG&A Expenses | 156.10M | 157.57M | 160.57M | 163.33M | 171.29M |
| Depreciation & Amortization | 1.70M | 1.70M | 1.70M | 1.70M | 1.70M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 325.71M | 334.30M | 344.43M | 354.24M | 367.68M |
| Operating Income | -136.19M | -155.34M | -167.15M | -185.47M | -193.18M |
| Income Before Tax | -141.89M | -159.60M | -195.35M | -213.57M | -215.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -141.89 | -159.60 | -195.35 | -213.57 | -215.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 55.00K | 103.00K | 104.00K | 104.00K | 79.00K |
| Net Income | -141.84M | -159.49M | -195.24M | -213.47M | -215.06M |
| EBIT | -136.19M | -155.34M | -167.15M | -185.47M | -193.18M |
| EBITDA | -117.41M | -136.09M | -146.95M | -164.10M | -171.15M |
| EPS Basic | -0.96 | -1.09 | -1.34 | -1.47 | -1.48 |
| Normalized Basic EPS | -0.58 | -0.66 | -0.72 | -0.80 | -0.84 |
| EPS Diluted | -0.96 | -1.09 | -1.34 | -1.47 | -1.48 |
| Normalized Diluted EPS | -0.58 | -0.66 | -0.72 | -0.80 | -0.84 |
| Average Basic Shares Outstanding | 591.80M | 588.40M | 585.62M | 582.81M | 579.79M |
| Average Diluted Shares Outstanding | 591.80M | 588.40M | 585.62M | 582.81M | 579.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |